source
- Blackstone invests $250 million in Anagram to address cystic fibrosis complicationBlackstone Life Sciences announced a $250 million investment in Anagram, a biotech focused on cystic fibrosis complications. The funding is part of one of the largest private investment funds in t…
- Entrada's Duchenne drug shows disappointing early data, shares tumbleEntrada disclosed initial results from a low‑dose version of its exon‑44 skipping therapy for Duchenne muscular dystrophy. The data, collected from six patients, failed to meet the company’s expect…